Shantel
Deloitte announced today that Frank D’Amelio, former executive vice president and chief financial officer at Pfizer Inc., has been appointed independent senior advisor, U.S. CFO Program, Deloitte LLP, serving as the “CFO-in-residence.” In this role, D’Amelio will serve as an independent advisor to clients, senior leadership, and Deloitte teams, providing his strategic guidance on the finance function and the evolving role of the CFO.
“Deloitte’s CFO Program has long been recognized for its prestige in advising current and future finance leaders through the challenges of a continually evolving business landscape. I am honored and excited to become the CFO-in-residence of this world class program as we continue the mission of advising CFOs through the complexities of the role. Frank D’Amelio, independent senior advisor, U.S. CFO Program, Deloitte LLP
D’Amelio’s responsibilities will range broadly, including playing a key role in CFO Transition Lab™ sessions, CFO Forums, Deloitte’s annual CFO Vision™ conference, and the CFO Program’s Next Generation CFO Academies. Further, he will lend his experience and insights to Deloitte’s quarterly CFO Signals™ survey and CFO 4Sight webinar, and biweekly CFO Insights series.
“Given his vast experience as a CFO, including having helped lead Pfizer through the global COVID-19 pandemic, Frank D’Amelio brings a wealth of knowledge and insights, as well as the skill set required to advise CFOs through their most pressing obstacles. We are thrilled to formally welcome Frank to the CFO Program team as our CFO-in-residence.”Steve Gallucci, national managing partner, U.S. CFO Program, Deloitte LLP, and global leader, Deloitte Touche Tohmatsu Limited
D’Amelio served as executive vice president and chief financial officer of Pfizer Inc. from 2007 to 2022. During his tenure, he was responsible for finance, business development and certain business operations, including information technology, procurement, and real estate. D’Amelio led the acquisition and integration of Wyeth Pharmaceuticals, King Pharmaceuticals, Hospira Inc., Anacor Pharmaceuticals Inc., and Medivation Inc., as well as the spin-off of Pfizer’s animal health business, Zoetis, the sale of its nutrition business to Nestlé and Capsugel business to KKR, the combination of Pfizer’s Upjohn business with Mylan to create Viatris, and the combination of Pfizer and GSK consumer healthcare businesses in a joint venture. In total, D’Amelio oversaw business development transactions at Pfizer of approximately $200 billion. During D’Amelio’s term as Pfizer’s CFO, the company’s market cap increased by almost $165 billion.
In addition to his role as CFO, D’Amelio was also responsible for Pfizer’s global supply chain from 2010-2011 and again from 2018-2021, which included the manufacturing and distribution of the COVID-19 vaccine, of which more than 3 billion doses were made in the first year of production.
About Deloitte’s CFO Program
The CFO Program brings together a multidisciplinary team of Deloitte leaders and subject-matter specialists to help CFOs stay ahead in the face of growing challenges and demands. The program harnesses our organization’s broad capabilities to deliver forward thinking and fresh insights for every stage of a CFO’s career—helping CFOs manage the complexities of their roles, tackle their company’s most compelling challenges, and adapt to strategic shifts in the market. For more on Deloitte’s CFO Program and offerings, please click here.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax, and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 7,000 private companies. Our people come together for the greater good and work across the industry sectors that drive and shape today’s marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthier society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Building on more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 415,000 people worldwide connect for impact at www.deloitte.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
